Literature DB >> 8585752

GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets.

D M Ryan1, J Ticehurst, M H Dempsey.   

Abstract

GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a novel viral neuraminidase (sialidase) inhibitor which, following intranasal administration in ferrets, is at least 100 to 1,000 times more effective than ribavirin and amantadine against influenza A and B viruses. It retains its activity even when treatments are delayed until 24 h postinfection and has no effect on the serum antibody response to infection.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8585752      PMCID： PMC162991          DOI： 10.1128/AAC.39.11.2583

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  4 in total

1.  Rational design of potent sialidase-based inhibitors of influenza virus replication.

Authors:  M von Itzstein; W Y Wu; G B Kok; M S Pegg; J C Dyason; B Jin; T Van Phan; M L Smythe; H F White; S W Oliver
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

2.  4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro.

Authors:  J M Woods; R C Bethell; J A Coates; N Healy; S A Hiscox; B A Pearson; D M Ryan; J Ticehurst; J Tilling; S M Walcott
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

3.  Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection.

Authors:  G J Alexander; J Brahm; E A Fagan; H M Smith; H M Daniels; A L Eddleston; R Williams
Journal:  Lancet       Date:  1987-07-11       Impact factor: 79.321

4.  Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase).

Authors:  D M Ryan; J Ticehurst; M H Dempsey; C R Penn
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191
  4 in total
  19 in total

Review 1.  Zanamivir.

Authors:  S L Waghorn; K L Goa
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

2.  Chemoprophylaxis of influenza A virus infections, with single doses of zanamivir, demonstrates that zanamivir is cleared slowly from the respiratory tract.

Authors:  R J Fenton; P J Morley; I J Owens; D Gower; S Parry; L Crossman; T Wong
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

Review 3.  Zanamivir: an update of its use in influenza.

Authors:  Susan M Cheer; Antona J Wagstaff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.

Authors:  S Bantia; C D Parker; S L Ananth; L L Horn; K Andries; P Chand; P L Kotian; A Dehghani; Y El-Kattan; T Lin; T L Hutchison; J A Montgomery; D L Kellog; Y S Babu
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

5.  Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.

Authors:  D B Mendel; C Y Tai; P A Escarpe; W Li; R W Sidwell; J H Huffman; C Sweet; K J Jakeman; J Merson; S A Lacy; W Lew; M A Williams; L Zhang; M S Chen; N Bischofberger; C U Kim
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

6.  Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071.

Authors:  W Li; P A Escarpe; E J Eisenberg; K C Cundy; C Sweet; K J Jakeman; J Merson; W Lew; M Williams; L Zhang; C U Kim; N Bischofberger; M S Chen; D B Mendel
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

7.  Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en.

Authors:  L V Gubareva; M J Robinson; R C Bethell; R G Webster
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

8.  Analysis of oseltamivir resistance substitutions in influenza virus glycoprotein neuraminidase using a lentivirus-based surrogate assay system.

Authors:  Jennifer Tisoncik-Go; Katie S Cordero; Lijun Rong
Journal:  Virol Sin       Date:  2013-02-06       Impact factor: 4.327

9.  Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071.

Authors:  C Y Tai; P A Escarpe; R W Sidwell; M A Williams; W Lew; H Wu; C U Kim; D B Mendel
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

Review 10.  New approaches to influenza chemotherapy. Neuraminidase inhibitors.

Authors:  D P Calfee; F G Hayden
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.